Skip to content

Improving symptoms of intermittent claudication in patients with erectile dysfunction and peripheral vascular disease: a pilot study assessing the benefit of daily dosing with Cialis (tadalafil) 10 mg

Improving symptoms of intermittent claudication in patients with erectile dysfunction and peripheral vascular disease: a pilot study assessing the benefit of daily dosing with Cialis (tadalafil) 10 mg

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN40898239
Enrollment
20
Registered
2007-12-05
Start date
2007-09-19
Completion date
Unknown
Last updated
2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erectile dysfunction, peripheral vascular disease Circulatory System Peripheral vascular disease

Interventions

Suitably screened and consenting patients will undertake an Exercise Tolerance Test (ETT) (modified Bruce protocol). Once baseline is established (two tests, 2 weeks apart), Tadalafil 10 mg daily or p

Sponsors

Guy's and St Thomas' NHS Foundation Trust (UK)
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Male aged 40 - 80 years 2. Erectile dysfunction (Sexual Health Inventory for Men [SHIM] score less than 21) 3. Peripheral vascular disease (PVD) (confirmed by previous ultrasound studies)

Exclusion criteria

Exclusion criteria: 1. Contraindication to PDE 5 inhibitor 2. Inability to undertake an exercise tolerance test

Design outcomes

Primary

MeasureTime frame
Total number of minutes/seconds on the exercise treadmill. Time to first report of leg pain will be recorded, measured at the end of weeks 3, 4 and 6

Secondary

MeasureTime frame
Change in score on the Walking Impairment Questionnaire and the Peripheral Artery Disease Symptom Scale, measured at the end of weeks 3, 4 and 6

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026